https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gosh-researchers-receive-ucl-business-award/
GOSH researchers receive UCL Business Award
23 Jun 2017, 12:57 p.m.
Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.
Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.
Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.
Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.
Creating communities and lasting involvement
At GOSH, patient and public involvement and engagement (PPIE) builds lasting relationships and communities that shape research over time.
Building trust in data and research
At GOSH, patients and young people are helping researchers understand not just what data can do, but how it should (and shouldn’t) be used, explained and protected.
Celebrating 25 years of saving children’s lives with gene therapy
Marking 25 years since delivering the first ground-breaking gene therapy here at GOSH, having now treated more than 135 children with rare and life-threatening conditions across the world.